Exploring the Next Generation of Cancer Genomics at BSGM
News Sep 12, 2013
Oxford Gene Technology (OGT) is inviting delegates of the British Society for Genetic Medicine (BSGM) conference to join its seminar entitled “Genomic profiling of cancer - from aCGH to NGS” on Tuesday 17 September, 12.30-13.30.
Professor Bass Hassan, Professor of Medical Oncology at the University of Oxford, will be guest speaker at the seminar, where he will discuss his latest research: “Integrating NGS technology into a bench to bedside clinical programme in rare cancers”.
Professor Hassan is a close collaborator with OGT, whose expertise in genomic technologies is central to his research.
In a recent study working on the genomic characterization of a number of sarcoma cell lines, he benefited from OGT’s expertise in areas including targeted sequencing (exome and cancer panels), low-depth whole genome sequencing, RNA-Seq and aCGH.
As a “hot topic” in medical genetics, the seminar presents an ideal opportunity for researchers to hear more about the clinical application of NGS.
OGT’s microarray and sequencing products and services enable rapid access to meaningful, high-quality results. A range of cancer-specific options are available, including the SureSeq™ Solid Tumour Panel NGS Service and CytoSure arrays optimized for the rapid detection of CNV and LOH in haematological and solid tumours.
Delegates of BSGM conference can also visit booth 25, where they will not only have the chance to discuss how OGT can enhance their research, but can also enter into the prize draw to win an Amazon Kindle Fire Tablet.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018